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Highlights 
 
 Serum mitochondrial DNA contents, one of the potential mitochondrial DAMPs, were 
elevated after aSAH over two weeks 
 
 Different mitochondrial genes (Cyt B, D-Loop and COX-1) showed association with 
post-SAH complications and clinical outcome 
 
 Elevated serum mitochondrial DNA and their associations with post-SAH 
complications and clinical outcome implicate an important role of mtDNA in systemic 
inflammation after aSAH 
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Abstract 
Aneurysmal subarachnoid hemorrhage (aSAH) is a highly complex disease. Majority of 
aSAH survivors confront post-SAH complications including cerebral vasospasm (CVS) and 
delayed cerebral ischemia (DCI) that mainly influence the clinical outcome. Tissue damage 
during early brain injury may lead to release of damage associated molecular pattern 
molecules (DAMPs) that may initiate and sustain inflammation during the course of aSAH 
through activation of pattern recognition receptors. Mitochondrial DNA (mtDNA) due to 
unmethylated CpG motifs acts as a DAMP via binding to toll-like receptor-9. The aim of this 
study was to investigate the cell free circulating mtDNA in the systemic circulation of aSAH 
patients and its association with post-SAH complications and clinical outcome. 
The DNA was extracted from the serum of 80 aSAH patients at days 1, 3, 5, 7, 9, 11, 13 and 
from 18 healthy controls. Three representative mitochondrial gene fragments including 
Cytochrome B (CytB), D-Loop and Cytochrome c oxidase subunit-1 (COX-1) were quantified 
using a Taqman-probes based qPCR. Levels of mtDNA were quantified from standard 
curves generated using mtDNA extracted from HepG2 cell mitochondria. Clinical outcome of 
the patients was assessed by Glasgow outcome scale (GOS) and modified Rankin scale 
(mRS). Clinical data and post-SAH complications were recorded from patient’s record file. 
Serum D-Loop and COX-1 were significantly elevated early after aSAH and remained high 
over first 2 weeks. CytB levels were however, initially unchanged but elevated later at day 7 
as compared to healthy controls. Cumulative levels measured over two weeks  showed 
significant correlations with post-SAH complications including a negative correlation of D-
Loop with pneumonia infection, hydrocephalus and occurrence of epilepsy, a positive 
correlation of Cyt B with occurrence of CVS and a negative correlation of COX-1 with 
occurrence of systemic infections and seizures. Cumulative D-Loop values negatively 
correlated with clinical outcome. Our data suggest that mtDNA may directly or indirectly 
influence post-SAH complications and clinical outcome. 
Keywords 
Mitochondrial DNA, DAMPs, aneurysmal subarachnoid hemorrhage, Cytochrome B, D-Loop, 
Cytochrome c oxidase. 
Abbreviations 
aSAH: Aneurysmal subarachnoid hemorrhage; CVS: cerebral vasospasm; DCI: delayed 
cerebral ischemia; DAMPs: damage associated molecular pattern molecules; mtDNA: 
Mitochondrial DNA; CytB: Cytochrome B; COX-1: Cytochrome c oxidase subunit-1; GOS: 
Glasgow outcome scale; mRS: modified Rankin scale; PRRs: pattern recognition receptors; 
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TFAM: mitochondrial transcription factor A; CT: computed tomography; CT-A: CT 
angiography; DSA: digital subtraction angiography; NICU: neuro-intensive care unit; TCD: 
transcranial Doppler; CT-P: CT perfusion; MTT: mean transient time; MAP: mean arterial 
blood pressure; IVH: intraventricular hemorrhage; ICB: intracerebral bleeding; CI: cerebral 
ischemia; VP-Shunt: ventriculoperitoneal shunt; H&H: Hunt and Hess grade; DIND: delayed 
ischemic neurological deficits 
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1. Introduction 
Subarachnoid hemorrhage (SAH) is a subtype of hemorrhagic stroke accounting for only 5% 
of all stroke events. The mortality afflicted by subarachnoid hemorrhage is around 50% (van 
Gijn and Rinkel, 2001) and incidence, although varies geographically, is around 10 per 
100,000 persons per year (Monstrey, 1998). Approximately 85% of SAH are due to rupture of 
intracranial aneurysms (Macdonald and Schweizer, 2017; van Gijn and Rinkel, 2001). 
Aneurysmal SAH (aSAH) affects at relatively younger age, around the mean age of 55 years 
and renders one third of the survivors dependent due to significant disability (van Gijn and 
Rinkel, 2001).  
In the pathophysiology of aSAH, which is highly complex, two phases of brain injury have 
been described. The early brain injury occurs within 72 hours of aSAH due to transient global 
cerebral ischemia as a consequence of increased intracranial pressure and due to the 
toxicity of the extravasated blood and its catabolic products. The delayed brain injury phase 
exists after 72 hours after aSAH with delayed cerebral ischemia (DCI) as the prominent 
deteriorating complication during this phase (Macdonald and Schweizer, 2017). Evidence 
suggests that inflammation plays a key role from aneurysm formation to its rupture and in 
post-SAH complications (Aoki et al., 2017; Lucke-Wold et al., 2016; Miller et al., 2014; 
Provencio, 2013). 
Mitochondria, due to their endosymbiotic nature, share many features to their ancestral 
bacteria (Galluzzi et al., 2012; Krysko et al., 2011) and are an important source of damage 
associated molecular pattern molecules (DAMPs). DAMPs released upon cellular injury from 
various cell compartments can be recognized by pattern recognition receptors (PRRs) on 
immune cells, leading to their activation and thus, upregulation of inflammation. In recent 
years, mitochondria have been recognized as a host of different DAMPs including TFAM 
(mitochondrial transcription factor A), N-formyl peptides, cardiolipin and hypomethylated/ 
non-methylated mitochondrial DNA, which are released upon cell stress, injury and necrosis 
(Galluzzi et al., 2012). Mitochondrial DNA (mtDNA) has been identified to induce TNF 
secretion from splenocytes and cause arthritis in mice joints on injection (Collins et al., 2004). 
In 2010, (Zhang et al. (2010b)) showed that circulating mtDNA can cause inflammation owing 
to its resemblance with bacterial CpG motifs and binding to toll like receptor 9 (TLR-9) on 
innate immune cells. There is now increasing evidence that mtDNA can upregulate innate 
immune response through several PRRs, most importantly TLR-9, NLRP3-, NLRC4-, AIM2-
inflammasome complex and cGAS-STING (Boyapati et al., 2017; West and Shadel, 2017). 
The systemic levels of mtDNA has been shown to be raised in different diseased conditions 
such as sepsis (Kung et al., 2012), trauma (Lam et al., 2004; Mohamed et al., 2016), 
meningitis (Lu et al., 2010), HIV infection (Perez-Santiago et al., 2016), acute myocardial 
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infarction (Wang et al., 2015), autism (Zhang et al., 2010a), hepatic transplantation (Hu et al., 
2015) and hemodialysis (Eleftheriadis et al., 2014). Multiple studies have shown that mtDNA 
as a potential biomarker of different neoplastic conditions such as prostate cancer (Ellinger et 
al., 2008), germ cell cancer (Ellinger et al., 2009) and breast cancer (Xia et al., 2014). A few 
studies have shown elevated circulating cell free mtDNA and its biomarker and prognostic 
potential in connection to diseases involving CNS pathologies (Lu et al., 2010; Mathew et al., 
2012; Perez-Santiago et al., 2016; Podlesniy et al., 2013; Podlesniy et al., 2016a; Podlesniy 
et al., 2016b; Sondheimer et al., 2014; Varhaug et al., 2016). Role of mtDNA in the context of 
aSAH has not been investigated in detail. 
Tissue damage during early brain injury may lead to release of damage associated molecular 
pattern molecules (DAMPs) that may initiate and sustain inflammation during the course of 
aSAH. The primary aim of this study was to investigate the systemic levels of mtDNA after 
aSAH. The secondary aim was to determine the association of mtDNA with post-SAH 
complications and clinical outcome of the patients. 
2. Methodology 
2.1. Patient Population 
This study consists of 80 consecutive aSAH patients, which were recruited in the 
neurosurgery unit of the University Hospital Bonn during 2012 to 2016. Patients underwent 
standard diagnostic and treatment protocols as per institutional guidelines and were destined 
to either neurosurgical clipping or endovascular coiling of bleeding aneurysms based on an 
interdisciplinary decision. The inclusion criteria were aSAH patients presenting within 24 
hours of onset of signs and symptoms. The exclusion criteria were age equal to or less than 
18 years, presenting after 24 hours after the onset of symptoms, traumatic brain injury, 
ischemic stroke, SAH due to arteriovenous malformations or other reasons, signs of 
imminent death, not providing informed consent and pregnancy. Peripheral blood samples 
were collected in serum Monovette gel tubes (Sarstedt, Germany) from aSAH patients at day 
1, 3, 5, 7, 9, 11, 13 and centrifuged at 3000 rpm for 10 minutes (Sigma, Germany).Control 
peripheral blood samples were obtained from 18 healthy volunteers. The serum was stored 
at -80 °C until analysis. The leucocyte counts and CRP values were retrieved from patients’ 
records. This study was performed according to the guidelines of the Helsinki declaration and 
was approved by the local ethical committee of the medical faculty of the University of Bonn 
(Reference Number: LfD 138/ 2011 and 258/15). 
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2.2. Clinical monitoring and treatment 
We followed our standardized diagnostic and treatment regimen. SAH was confirmed by 
computed tomography (CT) scan. CT angiography (CT-A) and digital subtraction 
angiography (DSA) were performed for further evaluation of the aneurysm. The treatment 
decision (coiling/ clipping) was based on an interdisciplinary approach. We followed an early 
treatment strategy (within 24 hours of admission). Our treatment protocol at the neuro-
intensive care unit (NICU) included hourly neurological monitoring, continuous invasive blood 
pressure and body temperature measurements, daily transcranial Doppler (TCD) and the 
application of nimodipine for 21 days starting from the day of admission. Generally, patients 
who were not clinically assessable were screened for vasospasm by daily TCD and DSA on 
day 7 after ictus. CT-A and CT perfusion (CT-P) were performed upon suspicion of CVS to 
confirm the presence of the latter. The patients having significant perfusion deficits with 
mean transient time (MTT) above 6 seconds in CT-P were considered to be treated. CVS 
patients were treated with induced hypertension using catecholamines, maintaining a target 
mean arterial blood pressure (MAP) at around 110 mm Hg until resolution of CVS. 
Hypertensive treatment was stopped after final CT-A and CT-P showed no further evidence 
of CVS with perfusion deficits. 
2.3. Isolation of serum DNA 
Cell free circulating DNA in the serum of aSAH patients and controls was isolated using 
QIAMP DNA mini kit (QIAGEN, Germany) by following the manufacturer’s instructions with 
slight modifications. Briefly, the serum samples were centrifuged for 3 mins at 6000 rpm 
(Eppendorf, Germany) to get rid of any contaminating cellular debris and obtain cell free 
DNA. A 200 µl aliquot of serum was applied to 20 µl proteinase K and 200 µl lysis buffer and 
incubated for 20 minutes at 56 °C. Afterwards, 230 µl of absolute alcohol was added and the 
mixture was applied to the provided columns after a brief spin down. The columns were 
washed twice sequentially with the provided washing buffers and finally, DNA was eluted 
from the column using 50 µl of elution buffer. The extracted DNA was stored at -80 °C until 
qPCR quantification. 
2.4. Generation of mtDNA for standard curves 
The mtDNA was extracted from the mitochondria isolated from HepG2 cells as described 
previously (Schafer et al., 2016). This mtDNA was then used as template to amplify different 
mt gene fragments i.e., mt Cytochrome B (mt CytB), mt D-Loop (mt D-Loop) and mt 
Cytochrome c oxidase subunit I (mt COX-1) by using following primers: mtCytB Fwd: 5’- CCT 
CCA AAT CAC CAC AGG A -3’, Rev: 5’- TGA GTA GAG AAA TGA TCC GTA ATA -3’ 
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(Eurogentec, Belgium); mtD-Loop Fwd: 5’- ATC AAC CCT CAA CTA TCA -3’, Rev: 5’- ACT 
GTA ATG TGC TAT GTA -3’; and mtCOX-1 Fwd: 5’- TCA TCT GTA GGC TCA TTC -3’, Rev: 
5’- GGC ATC CAT ATA GTC ACT -3’ (Invitrogen, Germany).  A 2 µL of mtDNA template was 
applied to a 50 µL PCR reaction volume containing 40 nM concentrations of the above 
mentioned primers. The PCR profile was initial denaturation at 95 °C for 5 mins followed by 
40 cycles of 95 °C for 1 min, 55 °C for 1 min and 72 °C for 1.5 min. The PCR products were 
validated by gel electrophoresis and were then purified by High Pure PCR Product 
Purification Kit (Roche, Germany). Purified mitochondrial gene fragments were then 
quantified by using nanodrop (Thermoscientific, Germany) and finally serial dilutions were 
prepared using sterilized TE buffer (pH 7.4) ranging from 100 ng/ml to 1 pg/ml.  
2.5. Real time PCR quantification of mtDNA 
A real time PCR approach based on Taqman probes labelled with 6-carboxyflourescein (6-
FAM) on their 5’ end and a non-fluorescent minor groove binder (MGB) on their 3’ end was 
established to quantify serum mtDNA levels. The following primers were employed for qPCR: 
mt CytB Fwd: 5’- AACCGCCTTTTCATCAATCG -3’, Rev: 5’- 
TAGCGGATGATTCAGCCATAATT -3’; mt D-Loop Fwd: 5’- 
TCAACTATCACACATCAACTGCAACT 3’, Rev: 5’- GGGTAGGTTTGTTGGTATCCTAGTG -
3’, and mt COX-1 Fwd: 5’- TCATCTGTAGGCTCATTCATTTCTCT -3’, Rev: 5’- 
TCTACTATTAGGACTTTTCGCTTCGA -3’. The sequences of Taqman Probes used were as 
follows: mt CytB 5’-6-FAM-CCACATCACTCGAGACGT-MGB-Eclipse-3’, mt D-Loop: 5’- 6-
FAM-CAAAGCCACCCCTCA-MGB-Eclipse-3’ and mt COX-1: 5’-6-FAM-
TTTTCATGATTTGAGAAGCC-MGB-Eclipse-3’. Both the primers and probes were 
purchased from Eurogentec, Belgium. A qPCR was carried out using a reaction volume of 
12.5 µL consisting of Taqman Universal qPCR mastermix (Life Technologies, Germany), 900 
nM of each primer and 100 nM of the respective probe. The qPCR conditions were initial 
heating at 50 °C for 2 mins, then at 95 °C for 10 mins to activate the Taq Polymerase and 
finally 50 cycles of 95 °C for 15 sec and 60 °C for 1 min. The data was acquired at the end of 
each cycle. The serum mtDNA levels were then computed from the respective standard 
curves for each mitochondrial gene fragment. 
2.6. Statistical analysis 
The categorical variables were expressed as percentages and the continuous variables as 
mean ± SEM unless otherwise stated. The mtDNA levels were log transformed before 
analysis. Two tailed student’s t test was performed to compare two groups. The P value 
<0.05 was considered as a significant difference. Spearman’s rank correlations were 
assessed for any association of different post-SAH complications and clinical outcome with 
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different mtDNA genes. The data was analysed using Graphpad Prism version 5.00 for 
Windows (CA, USA). 
3. Results 
3.1. Patient characteristics 
The characteristics of the aSAH patient population has been summarized and represented in 
Table 1. 
3.2. Serum levels of mitochondrial Cytochrome B, D-Loop and Cytochrome C oxidase 
subunit-1 were elevated after aSAH 
The mt CytB levels were non-significantly elevated at day 1, 3, and 5 after aSAH as 
compared to healthy controls (Fig. 1A). However, at day 7 mt CytB levels were significantly 
raised in aSAH patients as compared to HC and remained significantly high till day 13. The 
mt CytB levels appeared to be slowly released into systemic circulation, peaking at day 9 and 
then started to decline (Fig. 1A). The levels of another gene fragment mt D-Loop were 
significantly higher early at day 1 and remained high till day 13 in serum of patients with 
aSAH as compared to healthy controls (Fig. 1B). Mitochondrial gene fragment of 136 bp was 
quantified from mtDNA encoding mt COX-1. Similar to mt D-Loop, mt COX-1 levels were 
significantly increased very early after aSAH as compared to HC at day 1 and remained 
elevated till day 13 (Fig. 1C). The release pattern of mt COX-1 in systemic circulation after 
aSAH was almost identical to mt D-Loop, however, all the quantified gene fragments reached 
peak levels at day 9 and then, started to decline. Interestingly, this represents an important 
time period during which post SAH complications likely occur and lead to secondary 
deterioration of patients. 
3.2.1. Serum mt CytB and post SAH complications 
For further analysis whether mt CytB levels influence the post SAH complications, we 
dichotomized the patients into two groups and compared the values of mtDNA in patients 
with or without a specific complication. Analysis was performed for severity of aSAH, 
treatment modality, location of aneurysms, development of different complications including 
cerebral vasospasm, delayed cerebral ischemia, CNS or systemic infections, seizures, 
hydrocephalus and clinical outcome. Serum levels of mt CytB tended to be higher in male 
patients with significant differences seen on day1, day 3 and day 9 (Fig. 2A). A significant 
difference existed only on day 1 between the patients who had intracerebral bleeding (ICB) 
as compared to the patients without intraventricular hemorrhage (IVH) and intracerebral 
bleeding (ICB). There was no impact of infections on mt CytB levels (Fig. 2C). Subgroup 
analysis based on the development of pneumonia, meningitis, and other infections (presence 
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of other infections such as UTI or in combination with pneumonia or meningitis) revealed 
significant lower mt CytB levels at day 9 among aSAH patients with pneumonia (Fig. 3D). 
Similarly, patients who developed cerebral infarction, here referred to as cerebral ischemia 
(CI), did not display any significant changes in mt CytB levels (Fig. 2E). However, further 
subgroup analysis between intervention related CI (aSAH patients who developed CI during 
to aneurysm treatment) detected in 24 hour cranial CT or DCI (aSAH patients where CI 
cause was not attributed to intervention) showed significantly reduced mt CytB levels at day 
3, day 9 and day 13 in patients with interventional CI compared to without CI. On the other 
hand the patients with delayed cerebral ischemia (DCI) showed elevated mt CytB levels at 
day 9, day 11 (p=0.05) and day 13, compared to interventional CI group (data not shown). 
Our data suggests that mt CytB levels are sensitive to CI resulting from aneurysmal 
treatment with neurosurgical clipping or endovascular coiling. 
 
 
Figure 1: Comparison of serum mtDNA between healthy controls (HC, n =18) and aSAH 
patients (n = 80). A. Serum mt Cyt B levels between healthy controls and aSAH patients. B. 
Serum mt D-Loop levels between healthy controls and aSAH patients. C. Serum mt COX-1 
levels between healthy controls and aSAH patients. Student’s t test, p < 0.05. 
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Figure 2: Comparison of mt Cyt B levels between different aSAH subgroups. A. Comparison 
of mt Cyt B levels between male (n = 30) and female (n = 50) aSAH patients. B. Comparison 
of mt Cyt B levels in patients showing No intraventricular hemorrhage and intracerebral 
bleeding (IVH+ICB) (n = 43) and only ICB (n = 16). C. Comparison of mt Cyt B levels 
between patients developing infections (n = 29) and no infections (n = 51). D. Comparison of 
mt Cyt B levels between patients with no infections (n = 51) and Pneumonia (n = 15). E. 
Comparison of mt Cyt B levels in aSAH patients showing cerebral ischemia (CI) (n = 33). F. 
Comparison of mt Cyt B levels between patients who have no CI (n = 47) and interventional 
CI (n = 17). Unpaired t test, p < 0.05 was considered as a significant difference. 
 
3.2.2. Serum mt D-Loop and post SAH complications 
An analysis analogous to mt CytB was performed with serum mt D-Loop levels. Serum mt D-
Loop levels were only significantly high on day 9 in males and on day 13 in patients with 
severe aSAH (H&H III-V) (Fig. 3A, B). Like mt CytB, serum mt D-Loop levels were only 
downregulated in patients with pneumonia on day 9 compared to patients without infections 
(Fig. 3C). Patients who experienced post-SAH seizures have lower levels of mt D-Loop DNA 
levels with significant difference on day 3 and day 7 (Fig. 3D). A similar trend was seen in 
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patients who required ventriculoperitoneal shunt (VP-Shunt) placement due to development 
of chronic hydrocephalus on day 1 and day 9 (Fig. 3E). Interestingly, mt D-Loop DNA levels 
seem to be higher with significance difference on day 9 in patients with good clinical outcome 
(mRS 0-2) (Fig. 3F). 
 
 
Figure 3: Comparison of mt D-Loop levels between different aSAH subgroups. A. 
Comparison of mt D-Loop levels between male (n = 30) and female (n = 50) aSAH patients. 
B. Comparison of mt D-Loop levels between patients with severe aSAH (Hunt & Hess grade 
(H&H) III-V, n = 51) and less severe aSAH (H&H I-II, n = 29). C. Comparison of mt D-Loop 
levels between patients with no infections (n = 51) and Pneumonia (n = 15). D. Comparison 
of mt D-Loop levels between patients who developed seizures (n = 24) and no seizures (n = 
56). E. Comparison of mt D-Loop levels between patients who developed chronic 
hydrocephalus (n = 25) and who do not (n = 55). F. Comparison of mt D-Loop levels between 
patients with good clinical outcome (modified Rankin scale (mRS) 0-2, n = 35) and poor 
outcome (mRS 3-6, n = 45). Unpaired t test, p < 0.05 was considered as a significant 
difference. 
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3.2.3. Serum mt COX-1 and post SAH complications 
Patients with ICB and the patients who have developed DIND (delayed ischemic neurological 
deficits) showed significantly higher mt COX-1 levels on day 1 and day 11, respectively (Fig. 
4A & B). Group of patients who developed seizure showed significantly lower mt COX-1 
levels on day 7 (Fig. 4C). Levels of mt COX-1 were significantly lower at day 3 and day 9 in 
patients who developed cerebral ischemia. Further dichotomy of patients who developed 
cerebral ischemia revealed significant lower  mt COX-1 levels in patients with intervention 
related ischemia compared to the patients without ischemia  at day 3,  9, 11 and13 (Fig. 4D, 
E). 
 
Figure 4: Comparison of COX-1 levels between different aSAH subgroups. A. Comparison 
of mt COX-1 levels in aSAH patients with No intraventricular hemorrhage and intracerebral 
bleeding (IVH+ICB) (n = 43) and only intracerebral bleeding (ICB) (n = 16). B. Comparison of 
mt COX-1 levels between patients with No delayed ischemic neurological deficits (DIND) (n = 
52) and with DIND (n = 28). C. Comparison of mt COX-1 levels between aSAH patients 
developing seizures (n = 24) and no seizures (n = 56). D. Comparison of mt COX-1 levels in 
aSAH patients showing cerebral ischemia (CI) (n = 33) and no CI (n = 47). E. Comparison of 
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mt COX-1 levels between patients who have no CI (n = 47) and interventional CI (n = 17). 
Unpaired t test, p < 0.05 was considered as a significant difference. 
3.3. Correlations of total serum mtDNA with different aSAH characters 
Serum mtDNA for different mitochondrial gene fragments revealed significant correlations 
with different aSAH parameters as represented in Table 2. Cumulative values of all these 
gene fragments measured over two weeks duration also showed significant correlations with 
different aSAH associated characters including a negative correlation of D-Loop with 
pneumonia, hydrocephalus and occurrence of epilepsy, a positive correlation of Cyt B with 
occurrence of CVS and a negative correlation of COX-1 with occurrence of systemic 
infections and seizures. Cumulative D-Loop values negatively correlated with clinical 
outcome (Supplementary Table 1). 
4. Discussion 
Aneurysmal subarachnoid hemorrhage, a morbid and lethal subtype of hemorrhagic stroke, 
is characterized by an intracranial bleed due to rupture of an intracranial aneurysm usually 
located at bifurcation of cerebral arteries (Macdonald, 2014; Suarez  et al., 2006). The 
consequent transient global cerebral ischemia and extravasated blood toxicity leads to early 
brain injury that comprise all the events occurring within 72 hours of aSAH (Cahill and Zhang, 
2009; Munoz-Guillen et al., 2013). Since the bleeding aneurysm can be obliterated from 
circulation by microsurgical clipping or endovascular coiling, but majority of the aSAH 
patients still experience a delayed deterioration phase after surviving the initial ictus 
(Macdonald, 2014). This delayed deterioration is the result of post-SAH complications such 
as cerebral vasospasm (CVS), hydrocephalus, rebleeding from the ruptured aneurysm, 
seizures, cortical spreading depression (CSD), and most importantly delayed cerebral 
ischemia (DCI) (Iadecola, 2009; Macdonald, 2014; Suarez  et al., 2006). The failure of the 
past aSAH research focused solely on the reversal of CVS (a major contributor to DCI) to 
improve clinical outcome, led to explore additional mechanisms of brain injury. Increasing 
evidence suggests that aSAH is characterized by a systemic inflammatory response 
(Chaudhry et al., 2017; McMahon et al., 2013; Savarraj et al., 2017; Yoshimoto et al., 2001). 
Sterile inflammation is the consequence of recognition of danger signal molecules or 
alarmins by the pattern recognition receptors (PRRs) on the immune cells. Such danger 
signal molecules are referred to as damage associated molecular patterns (DAMPs) or 
pathogen associated molecular patterns (PAMPs) depending on whether they are derived 
from stressed, injured and necrotic cells or from invading pathogens, respectively(Chen and 
Nuñez, 2010; Takeuchi and Akira, 2010). Over the past, mitochondria have gained value as 
a potential host of different DAMPs. A great body of evidence supports the role of mtDNA as 
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a DAMP mediating inflammation via different PRRs such as TLR-9, NLRP3-, NLRC4-, AIM2-
inflammasome complex and cGAS-STING (Boyapati et al., 2017; West and Shadel, 2017). 
The current study aimed to investigate the temporal profile of systemic release of mtDNA 
after aSAH and assess its association with post-SAH complications and clinical outcome. 
The systemic levels of mtDNA were elevated in aSAH patients compared to healthy controls. 
Interestingly, mtDNA for D-Loop and COX-1 were significantly higher from day 1 until day 13 
in aSAH patients, however, mt CytB levels were significantly elevated at day 7 (Fig. 1). This 
suggests that different mtDNA gene fragments are differentially released into systemic 
circulation after aSAH. Interestingly, all of investigated mtDNA gene fragments showed a 
secondary delayed increase with a peak at day 9, which coincides with the delayed 
deterioration phase. Our results are in agreement with the findings of Wang and coauthors 
who observed elevated mitochondrial ND2 levels in a small group of aSAH patients (Wang et 
al., 2013).  
Further subgroup analysis based on dichotomization of aSAH patients into two groups for 
different base line characters, development of post SAH complications and clinical outcome 
showed differentially elevated mtDNA gene products in some of base line characters and 
post SAH complications. Serum mtDNA levels of CytB and D-Loop were higher in males in 
comparison to female aSAH patients (Fig. 2A, 3A and Table 2). CytB and COX-1 mtDNA 
levels were sensitive to intracerebral bleeding on admission to hospital (Fig. 2B and 4A). 
There was non-significant difference in serum mtDNA levels in patients who developed 
infections. However, further subgrouping based on the type of infections revealed that 
mtDNA levels followed different trends and a significantly lower mt CytB and mt D-Loop 
levels were observed at day 9 in patients with pneumonia. Another interesting trend was 
seen in CytB and COX-1 mtDNA levels where mtDNA levels were down regulated in patients 
who developed intervention related cerebral ischemia as opposed to patients developing DCI 
or without cerebral ischemia. Whether this difference has some implications from immune 
paralysis may require further thorough investigations as immune depression is observed 
after aSAH. It is also known that mtDNA leads to immunosuppression via TLR-9 dependent 
mechanisms in cytotoxic T cells and deletion of cross presenting dendritic cells (Sarrafzadeh 
et al., 2011; Schafer et al., 2016). The aSAH patients experiencing convulsive seizures 
tended to have lower levels of both mt D-Loop and mt COX-1 levels, whereas in chronic 
hydrocephalus only mt D-Loop levels were downregulated. Another interesting difference, 
although significant at day 9, was seen in mt D-Loop levels where patients with poor clinical 
outcome (mRS 3-6) tended to have lower mt D-Loop levels compared to those with good 
outcome (mRS 0-2). However, this was in contrast to the findings of Wang et al. (2013) who 
found significant elevation of mtDNA at day 8 in poor outcome patients, but this difference 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16 
 
does not exist anymore after controlling for the aneurysm treatment effects (Wang et al., 
2013). Furthermore, the study of Wang et al., (2013) was comprised of a small population of 
patients (n = 21) with more patients in the poor outcome group (n = 15), which might be the 
reason for divergence from their findings.  
The increasing levels of mtDNA in peripheral circulation may likely involve mtDNA release 
from necrotic cells or probably the impairment of the DNA clearance mechanisms owing to 
systemic inflammation mediated organ damage in critically ill patients (Tsai et al., 2011). 
Inflammation can lead to increased leucocyte counts (Neil-Dwyer and Cruickshank, 1974) 
and interestingly mtDNA levels measured at different days were correlated with leucocytes 
counts (Table 2). However, cumulative levels of CytB and D-Loop mtDNA were positively 
correlated with leucocyte count (Supplementary Table 1), which is in agreement with 
previous findings (Tsai et al., 2011). This suggests that mtDNA may probably lead to 
leukocytosis owing to its DAMP nature. A negative correlation was found at different days 
between mtDNA and CRP levels. Systemic DNA levels has been reported to correlate with 
cerebral hematoma; however, we found a weak, but significant correlation among Fischer 
grade, cumulative mtDNA levels of CytB and COX-1 (Supplementary Table 2) (Rainer et al., 
2003). It has already been mentioned that mtDNA levels are upregulated after CNS insult 
and TLR-9 is the major receptor mediating inflammatory effects of mtDNA (Boyapati et al., 
2017). Therefore, TLR-9 represents an important target and different strategies based on 
oligodeoxynucleotides (ODN) aimed at antagonizing the inflammatory effects of TLR-9 
activation are under development through preclinical or early clinical studies (Hennessy et 
al., 2010; Hoque et al., 2013; Savva and Roger, 2013). Another approach based on 
molecular scavenging of the free nucleic acids by nuclear acid binding polymers has been 
shown to limit the inflammation in preclinical studies (Holl et al., 2016; Holl et al., 2013). 
Therefore, further dissection of the inflammation associated with mtDNA and TLR-9 axis in 
animal models of SAH is warranted to unveil the biomarker and therapeutic potential of this 
axis. 
Our study with human population has interesting findings, but with some limitations. First of 
all, our patient population is very heterogeneous with wide age range, inclusion of both sexes 
and diverse grade of severity of subarachnoid hemorrhage with Hunt and Hess grade I-V. All 
these factors may lead to increase the variation as reflected by our data showing that male 
patients had higher serum mtDNA D-Loop and Cyt B levels. Hence, due to the heterogeneity 
of aSAH population the data should be interpreted carefully for any implications. 
Moreover, the assessment of clinical outcome with common test batteries including GOS and 
mRS are not sensitive and roughly reflects the neurological status and hence, the discrete 
changes in neurological status may be overlooked. 
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Although with certain limitations, our data clearly demonstrates the elevated mitochondrial 
damage associated molecular patterns that might be implicated in an upregulated systemic 
inflammatory response after subarachnoid hemorrhage. 
5. Conclusion 
Systemic mtDNA levels were elevated after aSAH and display differential correlations with 
different aSAH associated characters, complications and clinical outcome.  
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Table 1: Characteristics of aSAH patients 
aSAH  (n) 80 
Age (years) (mean±SD) 56.97 (±12.00)  
Females (%) 62.5% 
Treatment modality 
Neurosurgical clipping (%) 
Endovascular coiling (%) 
 
48.8% 
51.3% 
Intraventricular hemorrhage: IVH (%) 12.5% 
Intracerebral bleeding: ICB (%) 20.0% 
ICB and IVH (%) 13.8% 
Hunt and Hess grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
6.3% 
30.0% 
28.8% 
16.3% 
18.8% 
Fischer grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
3 
1.3% 
2.5% 
85.0% 
12.5% 
Cerebral Vasospasm; CVS (%) 55.0% 
Cerebral Ischemia (%) 41.3% 
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Intervention related CI (%) 
DCI (%) 
21.3% 
20.0% 
Seizures (%) 30.0% 
VP-Shunt dependent hydrocephalus (%) 31.3% 
Infections (%) 
Pneumonia (%) 
Meningitis (%) 
Others (%) 
Pneumonia+Meningitis (%) 
Pneumonia+UTI (%) 
Meningitis+UTI (%) 
Misc. (Osteomyelitis, sepsis) (%) 
36.3% 
18.8% 
8.8% 
8.8% 
2.5% 
2.5% 
1.3% 
2.5% 
Delayed Ischemic Neurological Deficits; DIND (%) 35.0% 
Aneurysm location 
Anterior circulation (%) 
Posterior circulation (%) 
 
86.3% 
13.8% 
Glasgow Outcome Scale; GOS (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
8.8% 
12.5% 
30.0% 
7.5% 
41.3% 
Modified Rankin Scale; mRS (median) 
0 (%) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
6 (%) 
3 
2.5% 
31.3% 
10.0% 
8.8% 
21.3% 
17.5% 
8.8% 
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Table 2: Correlations of different mtDNA genes (mt CytB, mt D-Loop and mt COX-1) 
with different aSAH associated parameters 
Log mtDNA aSAH 
characters 
No. of XY 
pairs 
Spearman rho P value 95% CI 
CytB D1 Female 80 -0.254 0.023 -0.454 to 0.030 
CytB D1 Leucocytes D13 61 -0.315 0.014 -0.531 to -0.061 
CytB D3 Female 79 -0.221 0.051 -0.427 to 0.007 
CytB D3 Leucocytes D5 76 0.323 0.005 0.098 to 0.516 
CytB D3 Interventional CI 79 -0.243 0.031 -0.446 to -0.017 
CytB D5 Female 77 -0.243 0.033 -0.448 to -0.014 
CytB D5 CRP D13 32 -0.381 0.031 -0.650 to -0.027 
CytB D7 Female 79 -0.225 0.046 -0.431 to 0.002 
CytB D9 Female 78 -0.2316 0.041 -0.437 to -0.003 
CytB D9 Infarcts 78 -0.239 0.035 -0.444 to -0.011 
CytB D9 Interventional CI 78 -0.326 0.004 -0.517 to -0.105 
CytB D9 Leucocytes D11 57 0.306 0.020 0.042 to 0.531 
CytB D11 Leucocytes D11 55 0.375 0.005 0.114 to 0.588 
CytB D13 Interventional CI 70 -0.284 0.017 -0.492 to -0.045 
CytB D13 CRP D1 36 -0.392 0.018 -0.645 to -0.063 
CytB D13 CRP D13 28 -0.426 0.024 -0.696 to -0.052 
D-Loop D1 Chronic 
Hydrocephalus 
80 -0.280 0.012 -0.476 to -0.058 
D-Loop D1 CRP D1 43 -0.309 0.044 -0.564 to 0.000 
D-Loop D1 Leucocytes D13 61 -0.278 0.030 -0.501 to -0.020 
D-Loop D5 CRP D9 38 -0.337 0.038 -0.599 to -0.010 
D-Loop D7 CRP D11 33 0.360 0.040 0.008 to 0.632 
D-Loop D9 Chronic 
Hydrocephalus 
78 -0.289 0.010 -0.486 to -0.065 
D-Loop D9 GOS 78 0.288 0.011 0.063 to 0.485 
D-Loop D9 mRS 78 -0.274 0.015 -0.473 to -0.048 
D-Loop D9 Leucocytes D1 77 0.230 0.045 -0.001 to 0.437 
D-Loop D13 CRP D1 35 -0.405 0.016 -0.656 to -0.073 
COX1 D1 Leucocytes D13 61 -0.276 0.032 -0.499 to -0.018 
COX1 D3 CRP D3 41 -0.328 0.036 -0.584 to -0.013 
COX1 D3 Seizures 79 -0.224 0.047 -0.430 to 0.003 
COX1 D3 Interventional CI 79 -0.297 0.008 -0.491 to -0.075 
COX1 D5 CRP D1 41 -0.319 0.042 -0.577 to -0.003 
COX1 D7 Seizures 79 -0.246 0.029 -0.448 to -0.019 
COX1 D9 Infarcts 78 -0.234 0.039 -0.439 to -0.005 
COX1 D9 Interventional CI 78 -0.323 0.004 -0.514 to -0.101 
COX1 D11 Interventional CI 73 -0.336 0.004 -0.531 to -0.108  
COX1 D11 DIND 73 0.242 0.039 0.006 to 0.453 
COX1 D11 Leucocytes D11 55 0.305 0.024 0.0353 to 0.534 
COX1 D13 Interventional CI 70 -0.335 0.005 -0.534 to -0.102 
COX1 D13 CRP D1 36 -0.351 0.036 -0.616 to -0.016 
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Supplementary Table 1: Correlations of cumulative mtDNA levels of mt CytB, D-Loop 
and COX-1 measured over two weeks with different aSAH patient associated 
characters, complications and clinical outcome 
Log mt 
DNA 
Complications &  
Clinical Outcome 
Spearman 
rho 
P value 95% CI 
D-Loop GOS 0.113 0.010 0.024 to 0.200 
D-Loop mRS -0.104 0.019 -0.191 to -0.015 
D-Loop Gender -0.152 0.001 -0.238 to -0.064 
D-Loop Pneumonia -0.1330 0.003 -0.219 to -0.044 
D-Loop Chronic hydrocephalus -0.128 0.004 -0.215 to -0.039 
D-Loop Seizures -0.152 0.001 -0.238 to -0.064 
D-Loop Leucocytes 0.120 0.0110 0.025 to 0.212 
Cyt B CVS 0.101 0.019 0.014 to 0.187 
Cyt B CI -0.105 0.020 -0.190 to -0.018 
Cyt B Interventional CI -0.179 <0.000 -0.262 to -0.094 
Cyt B Pneumonia -0.149 0.001 -0.233 to -0.062 
Cyt B Others 0.1013 0.019 0.014 to 0.186 
Cyt B Fischer 0.113 0.009 0.026 to 0.198 
Cyt B Gender -0.2012 <0.000 -0.283 to -0.116 
Cyt B Leucocytes 0.123 0.008 0.030 to 0.213 
COX-1 CI -0.150 0.000 -0.232 to -0.066 
COX-1 Interventional CI -0.208 <0.000 -0.288 to -0.125 
COX-1 Fischer 0.100 0.018 0.015 to 0.183 
COX-1 Infections -0.117 0.005 -0.201 to -0.033 
COX-1 Pneumonia -0.107 0.011 -0.191 to -0.022 
COX-1 Meningitis -0.0834 0.049 -0.168 to 0.002 
COX-1 Seizures -0.094 0.026 -0.178 to -0.009 
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